Dr. A. Robert MacLeod

• 
  BioPharma-Montreal : Chercheurs - [Cached Version]
  Published on: 8/25/2001    Last Visited: 6/9/2002  

  Robert MacCleod
  
  MethylGene

• 
  Canadian IPO - [Cached Version]
  Published on: 12/13/1995    Last Visited: 10/26/2004  

  A. Robert MacLeod - Director, Biology

• 
  IBC's Drug Discovery Technology | About IBC's Drug... - [Cached Version]
  Published on: 1/12/2007    Last Visited: 1/12/2007  

  A. Robert MacLeod, Ph.D., Executive Director, Pharmacology and Cell Biology, MethylGene, Inc.

• 
  Le carrefour de la biotechnologie 2002 - Programme - [Cached Version]
  Published on: 7/6/2002    Last Visited: 3/9/2003  

  Dr. Robert MacLeod, Director Biology, METHYLGENE, Canada

• 
  MDS Capital Corp. - Partner Companies - [Cached Version]
  Published on: 2/10/2002    Last Visited: 10/30/2002  

  Robert MacLeod, Ph.D. Director, Biology

• 
  MGI PHARMA Investor Relations - [Cached Version]
  Published on: 10/18/2001    Last Visited: 1/31/2005  

  The two presentations were based upon research conducted under the direction of Dr. A. Robert MacLeod, assistant director of biology at MethylGene.

• 
  MethylGene :: August 7, 2006 - [Cached Version]
  Published on: 8/7/2006    Last Visited: 8/11/2009  

  A. Robert MacLeod, Executive Director of Pharmacology and Cell Biology of MethylGene, will present at IBC's 11th Annual World Congress in Boston on Wednesday, August 9th at 4:45 p.m. EDT.
  
  Dr. MacLeod's presentation entitled, "Novel, Orally Active Multi-Targeted Kinase Inhibitors of the c-Met and VEGF Receptors," will highlight MethylGene's multi-targeted kinase program for oncology. Dr. MacLeod will describe the broad-spectrum antitumour activity of our lead molecules that are potent inhibitors of a unique spectrum of kinases including the c-Met receptor, all three VEGF receptors as well as RON, Tie-2 and Flt-3 kinases. These targets are involved in tumour cell survival, tumour metastasis and angiogenesis.

• 
  MethylGene :: Management Team - [Cached Version]
  Published on: 10/28/2006    Last Visited: 10/28/2006  

  A. Robert MacLeod, Ph.D.Executive Director, Pharmacology and Cell Biology
  
  Dr. MacLeod joined us in 1996 and is currently Executive Director of Pharmacology and Cell Biology.He is a key participant in the efforts and growth of our multidisciplinary biology team and his earlier work led to the identification and IND filing of MG98.He has been a key contributor in the discovery and research of our oncology product candidates.He is author or co-author of over 20 publications and co-inventor on eight United States patents.Dr. MacLeod has been a member of two US-NIH-National Cancer Institute's Core Committees (Genetic Epidemiology and Gastro-intestinal Tumors) and has served as a scientific reviewer for Nature Genetics, Proceedings of the National Academy of Sciences and other high-impact journals.Dr. MacLeod received his Ph.D. from McGill University where he was involved with pioneering studies into the role of DNMT enzymes in oncogenic transformation.This work uncovered the potential of DNMT-specific inhibitors in the treatment of cancer.He then joined Isis Pharmaceuticals, Inc. where he studied mechanisms of novel cancer drugs before joining us.

• 
  MethylGene to Present at IBC's 11th Annual World... - [Cached Version]
  Published on: 8/7/2006    Last Visited: 8/7/2006  

  MONTREAL, QUEBEC--(CCNMatthews - Aug. 7, 2006) - MethylGene Inc. (TSX:MYG) today announced that A. Robert MacLeod, Executive Director of Pharmacology and Cell Biology of MethylGene, will present at IBC's 11th Annual World Congress in Boston on Wednesday, August 9th at 4:45 p.m. EDT.
  
  Dr. MacLeod's presentation entitled, "Novel, Orally Active Multi-Targeted Kinase Inhibitors of the c-Met and VEGF Receptors," will highlight MethylGene's multi-targeted kinase program for oncology.Dr. MacLeod will describe the broad-spectrum antitumour activity of our lead molecules that are potent inhibitors of a unique spectrum of kinases including the c-Met receptor, all three VEGF receptors as well as RON, Tie-2 and Flt-3 kinases.These targets are involved in tumour cell survival, tumour metastasis and angiogenesis.

• 
  Ontario Genomics Institute - [Cached Version]
  Published on: 10/23/2001    Last Visited: 6/2/2004  

  Both presentations were based on research conducted under the direction of MethylGene's Dr. Robert MacLeod.
  
  Neurochem Obtains $1.4 Million Grant for Fibrillex Study

Page:  1 2